Shopping Cart
Remove All
Your shopping cart is currently empty
PAR-4 Agonist Peptide, amide TFA (PAR-4-AP (TFA)), is a selective activator of the proteinase-activated receptor-4 (PAR-4) that does not affect PAR-1 or PAR-2, and its activity can be inhibited by a PAR-4 antagonist.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $30 | - | In Stock | |
| 5 mg | $88 | - | In Stock | |
| 10 mg | $148 | - | In Stock | |
| 25 mg | $251 | - | In Stock | |
| 50 mg | $358 | - | In Stock | |
| 100 mg | $518 | - | In Stock | |
| 200 mg | $715 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $141 | - | In Stock |
| Description | PAR-4 Agonist Peptide, amide TFA (PAR-4-AP (TFA)), is a selective activator of the proteinase-activated receptor-4 (PAR-4) that does not affect PAR-1 or PAR-2, and its activity can be inhibited by a PAR-4 antagonist. |
| In vivo | SCID mice demonstrate a markedly enhanced abdominal response to colorectal distension (CRD), with distension levels ranging from 0.04 to 0.1 mL amplifying the intensity of the EMG response from 384% to 132%, respectively, as compared to BALB/cBy controls (P<0.01; P<0.01; P<0.01; P<0.001). Activation of PAR-4 significantly mitigates this hypersensitivity (P<0.01, P<0.05; P<0.05; P<0.05)[1]. |
| Synonyms | PAR-4-AP (TFA), AY-NH2 (TFA) |
| Molecular Weight | 794.82 |
| Formula | C36H49F3N8O9 |
| Cas No. | 1228078-65-6 |
| Smiles | OC(=O)C(F)(F)F.C[C@H](N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccccc1)C(N)=O |
| Relative Density. | no data available |
| Color | White |
| Appearance | Solid |
| Sequence | Ala-Tyr-Pro-Gly-Lys-Phe-NH2 |
| Sequence Short | AYPGKF-NH2 |
| Storage | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | H2O: 100 mg/mL (125.81 mM), Sonication is recommended. DMSO: 250 mg/mL (314.54 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 5 mg/mL (6.29 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
H2O/DMSO
| ||||||||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.